Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2023 | Strategies to improve CAR-T outcomes in patients with LBCL

Wendy Osborne • 10 Feb 2023
CAR-T Meeting 2023
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Bendamustine CAR-T Polatuzumab vedotin Rituximab

Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, shares some insights into strategies to improve CAR-T outcomes in patients with large B-cell lymphoma (LBCL), highlighting the importance of patient selection and effective de-bulking during bridging. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Roche, Takeda, Pfizer, Servier, Kite Gilead, MSD, Novartis, Beigene, Astra Zeneca, Syneos, Autolus, Kyowa Kirin, Abbvie, Incyte, BMS/Celgene, Janssen

More from Wendy Osborne

2:03
Novel treatment approaches for early-stage DLBCL
Wendy Osborne • 24 Apr 2023
1:20
Improving patient outcomes in CTCL: clinical collaboration and novel agents
Wendy Osborne • 24 Apr 2023
2:19
Session highlights: autoSCT in T-cell lymphoma, classification updates and fertility preservation
Wendy Osborne • 24 Apr 2023
1:01
Pitfalls in the diagnosis of lymphoid malignancies: interpreting PET scans
Wendy Osborne • 24 Apr 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals